|
CN102531999A
|
|
Amorphous lercanidipine hydrochloride and preparation method thereof
|
|
CN102247376A
|
|
Compound solid preparation of valsartan and hydrochlorothiazide, and preparation method thereof
|
|
CN102321041A
|
|
Preparation method of linezolid
|
|
CN102336703A
|
|
Method for preparing roflumilast
|
|
CN102219752A
|
|
Crystal form D of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
|
|
CN102204907A
|
|
Pharmaceutical composition containing valsartan, and preparation method thereof
|
|
CN102188420A
|
|
Levetiracetam medicinal composition and preparation method thereof
|
|
CN102204910A
|
|
Pharmaceutical composition of moxifloxacin hydrochloride, and preparation method thereof
|
|
CN102002017A
|
|
Method for preparing febuxostat intermediate
|
|
CN101985451A
|
|
Preparation method of prasugrel intermediate
|
|
CN101985450A
|
|
Prasugrel salt and preparation method thereof
|
|
CN102002056A
|
|
Method for preparing intermediate of prasugrel
|
|
CN101926756A
|
|
Solid preparation of clopidogrel or pharmaceutically acceptable salt thereof
|
|
CN101723915A
|
|
Method for preparing Febuxostat intermediate
|
|
CN101735106A
|
|
Method for preparing biphenyl compound
|
|
CN101693017A
|
|
Medicament composition of levetiracetam and preparation process
|
|
CN101648839A
|
|
Green synthesis method of bromomethylbiphenyl compound
|
|
CN101659612A
|
|
Selective esterification method
|
|
CN101585842A
|
|
Research and control method of impurity B control method in clopidogrel
|
|
CN101560190A
|
|
Method for researching and controlling impurity E in Valsartan
|
